Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Stocks · News reference
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing
The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.
Correction: Bioprinting Market to Reach $5.1 Billion by 2030, Driven by Regenerative Medicine Demand and AI Integration
The global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030 at a 16.1% CAGR, driven by regenerative medicine demand, pharmaceutical adoption for drug discovery, reduced animal testing, and AI integration. North America leads with 38% market share, while emerging technologies like 4D bioprinting and organ-on-chip devices expand market boundaries.
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
The global gRNA (guide RNA) market is projected to grow from USD 518 million in 2024 to USD 2,950 million by 2034, representing a 19% CAGR. Growth is driven by increasing cancer research, infectious disease prevalence, technological innovation, and expanding applications in genome editing, functional genomics, diagnostics, cell & gene therapy, and agricultural biotechnology. Key market players include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, and others. Strategic partnerships and rising adoption of CRISPR technology in agriculture are major growth catalysts.